Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies
Open Access
- 4 May 2026
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 86 (6) , 909-925
Abstract
Large vessel vasculitides (LVV), including giant cell arteritis (GCA) and Takayasu arteritis (TAK), share common features such as inflammation of large sized arteries but differ in several key aspects, including age of onset and pathogenic mechanism. This narrative review gives an update of recent insights into pathogenesis of GCA and TAK, and discusses emerging targeted therapies based on these insights. It highlights omics-based signatures, ULK3 and SLAMF7 in GCA, EGR1 in TAK, alongside genetic and somatic risk factors such as clonal haematopoiesis (DNMT3A/TET2) linked to relapse and ischaemic vision loss in GCA, and the IL6R-p.Asp358Ala variant as a predictor of reduced interleukin (IL)-6 receptor blockade response. Common mechanisms include CD4⁺ T-cell, monocyte/macrophage, and B-cell infiltration with activation of IL-6, JAK/STAT/interferon, and IL-17 pathways. Giant cell arteritis is characterised by GM-CSF-driven macrophages and disrupted programmed cell death (PD)-1/PD-L1 checkpoint regulation, while TAK shows dominance of CD8⁺ T cells and tumour necrosis factor (TNF)-α signalling. Interleukin-6 receptor inhibitors (e.g., tocilizumab) show robust efficacy in GCA but with notable non-responders; the JAK inhibitor upadacitinib demonstrated efficacy in a Phase III study, whereas IL-17 blockade (secukinumab) yielded inconsistent results. In TAK, TNF inhibitors and tocilizumab are comparably effective; early data suggest Janus kinases (JAK) inhibitors promote remission, imaging improvement, and glucocorticoid sparing. Mavrilimumab (GM-CSF receptor blockade) is promising in GCA. Recent studies have increasingly focused on short-term glucocorticoid therapy in combination with biologic agents. Advances in biomarker research, including investigation of the IL-6 receptor and IL-17A gene polymorphisms, may enable more targeted therapeutic strategies.Keywords
Funding Information
- Medizinische Universität Graz
This publication has 117 references indexed in Scilit:
- Ustekinumab for the Treatment of Giant Cell ArteritisArthritis Care & Research, 2020
- Th1 and Th17 Cytokines Drive Inflammation in Takayasu ArteritisArthritis & Rheumatology, 2015
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesisArthritis & Rheumatism, 2012
- Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followupArthritis Care & Research, 2012
- Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritisArthritis Care & Research, 2010
- Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysisArthritis & Rheumatism, 2007
- Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisArthritis & Rheumatism, 2004
- A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritisArthritis & Rheumatism, 2002
- Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexateArthritis & Rheumatism, 1994